AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28922507 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 26002610 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1256
Study 26002610 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 1256
Study 25132778 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week instructor-led group aerobic exercise program (3 days/week, 10 min warm-up, 40 min exercise, 10 min cool-down, increasing intensity from 50% to 70% HRR)
Number of subjects: 60
Study 25132778 — intervention group
Group type: COMPARATOR
Intervention: Ordinary daily activities (control group)
Number of subjects: 60
Study 22564148 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly dosing after inadequate response to 40 mg eow dosing
Number of subjects: 349
Study 22564148 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg eow dosing
Number of subjects: 349
Study 22564148 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly dosing
Number of subjects: 349
Study 19104360 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive prenatal testing decision tool
Number of subjects: 496
Study 19104360 — intervention group
Group type: COMPARATOR
Intervention: Control (California Department of Health Services' educational booklet)
Number of subjects: 496
Study 17198705 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional GnRH‐agonist and recombinant FSH stimulation (IVO)
Number of subjects: 0
Study 17198705 — intervention group
Group type: COMPARATOR
Intervention: Minimally stimulated in vitro maturation (IVM) with recombinant FSH and FF‐MAS (0.1-20 microM)
Number of subjects: 0
Study 17198705 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM with FF‐MAS (20 microM) for 36 hours
Number of subjects: 0
Study 17198705 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM with FF‐MAS (1-10 microM) for 30 hours
Number of subjects: 0
Study 15987391 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-based sedation regime (initial dose 6 to 9 microg kg(‐1) h(‐1) titrated to response before the addition of midazolam)
Number of subjects: 105
Study 15987391 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-based sedation regime
Number of subjects: 105
Study 15987391 — intervention group
Group type: COMPARATOR
Intervention: Midazolam-based sedation regime with fentanyl or morphine
Number of subjects: 105
Study 12500172 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical castration
Number of subjects: 40
Study 12500172 — intervention group
Group type: COMPARATOR
Intervention: Control group with appropriate hormone levels
Number of subjects: 40
Study 9661626 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (12 IU/day)
Number of subjects: 18
Study 9661626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7814081 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 gel 0.5 mg
Number of subjects: 97
Study 3768242 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 8
Study 3768242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg)
Number of subjects: 8
Study 3768242 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg) plus Ketanserin (20 mg)
Number of subjects: 8
Study 3768242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30916381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 2180
Study 30916381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 2180
Study 30916381 — intervention group
Group type: COMPARATOR
Intervention: Control group (ADA-NEG patients)
Number of subjects: 2180
Study 29581212 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week Alert Program school curriculum delivered in weekly 1-hour lessons by trained classroom teachers.
Number of subjects: 363
Study 29581212 — intervention group
Group type: COMPARATOR
Intervention: Control conditions in clusters two to four (regular schooling before intervention).
Number of subjects: 363
Study 27171822 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined obturator nerve block (ONB) and femoral triangle block (FTB)
Number of subjects: 75
Study 27171822 — intervention group
Group type: COMPARATOR
Intervention: Single femoral triangle block (FTB)
Number of subjects: 75
Study 27171822 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 75
Study 27171822 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ONB and FTB
Number of subjects: 75
Study 24815544 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand Up and Sit Less intervention
Number of subjects: 43
Study 21628604 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg alone
Number of subjects: 24
Study 21628604 — intervention group
Group type: COMPARATOR
Intervention: Asenapine 5 mg under steady‐state valproate (500 mg bid for 9 days)
Number of subjects: 24
Study 20642579 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) with depigmented polymerized birch pollen extract
Number of subjects: 61
Study 20642579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 18828993 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving training (PST) via videoconferencing sessions for a year
Number of subjects: 61
Study 18828993 — intervention group
Group type: COMPARATOR
Intervention: Education-only control group
Number of subjects: 61
Study 18454251 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurexan
Number of subjects: 409
Study 18454251 — intervention group
Group type: COMPARATOR
Intervention: Valerian
Number of subjects: 409
Study 15363875 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 1001
Study 15363875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1001
Study 11755507 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol lowering
Number of subjects: 7
Study 11755507 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure lowering
Number of subjects: 7
Study 11755507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose lowering
Number of subjects: 7
Study 9065185 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy specimens obtained with a Vabra aspiration curette
Number of subjects: 2964
Study 7681957 — intervention group
Group type: EXPERIMENTAL
Intervention: Early AICD implantation
Number of subjects: 46
Study 7681957 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapeutic strategy
Number of subjects: 46
Study 3538786 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam mesylate
Number of subjects: 80
Study 3538786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31634137 — intervention group
Group type: EXPERIMENTAL
Intervention: Multichannel nerve stimulation using a 2 × 8 stimulation grid on the upper arm along the ulnar and median nerves.
Number of subjects: 0
Study 30103363 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal out‐patient prevention program with recovery interventions for 12 weeks
Number of subjects: 58
Study 30103363 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 58
Study 26743539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of purified Plasmodium falciparum sporozoites (n = 24)
Number of subjects: 30
Study 26743539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of purified Plasmodium falciparum sporozoites (n = 6)
Number of subjects: 30
Study 25629785 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance rehabilitation and training apparatus
Number of subjects: 7
Study 22429474 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent
Number of subjects: 695
Study 22429474 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent
Number of subjects: 695
Study 19149819 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E HIV vaccine
Number of subjects: 2546
Study 19149819 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance
Number of subjects: 2546
Study 19149819 — intervention group
Group type: EXPERIMENTAL
Intervention: Incarceration
Number of subjects: 2546
Study 19149819 — intervention group
Group type: EXPERIMENTAL
Intervention: Injecting behavior
Number of subjects: 2546
Study 19149819 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors
Number of subjects: 2546
Study 17495764 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alpha-lipoic acid (ALA) 600 mg
Number of subjects: 0
Study 17495764 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alpha-lipoic acid (ALA) 1200 mg
Number of subjects: 0
Study 17495764 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alpha-lipoic acid (ALA) 1800 mg
Number of subjects: 0
Study 15068403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine + haloperidol
Number of subjects: 0
Study 15068403 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol + placebo
Number of subjects: 0
Study 11428735 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler 200 microg
Number of subjects: 274
Study 11428735 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler 400 microg
Number of subjects: 274
Study 11428735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 9870877 — intervention group
Group type: EXPERIMENTAL
Intervention: cA2 at 5, 10, or 20 mg/kg
Number of subjects: 0
Study 9870877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8066109 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback to retrain the triceps muscle (n = 8)
Number of subjects: 16
Study 8066109 — intervention group
Group type: COMPARATOR
Intervention: Conventional movement training (n = 8)
Number of subjects: 16
Study 8066109 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Electromyographic biofeedback and Conventional movement training)
Number of subjects: 16
Study 3291085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 123
Study 3291085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 3291085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine and Placebo
Number of subjects: 123
Study 28707217 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% milk (12 g carbohydrates)
Number of subjects: 86
Study 28707217 — intervention group
Group type: EXPERIMENTAL
Intervention: apple juice (29 g carbohydrates)
Number of subjects: 86
Study 28707217 — intervention group
Group type: COMPARATOR
Intervention: water
Number of subjects: 86
Study 27011386 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbrokinase DLBS1033 490 mg 3 times daily
Number of subjects: 20
Study 27011386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26233677 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive motion-controlled games, 8 sessions over 4 weeks, average session time 26 minutes.
Number of subjects: 40
Study 26233677 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail),
Number of subjects: 40
Study 24256671 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusion (one pack of apheresis platelets)
Number of subjects: 28
Study 20843608 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test for Groups (TSST-G)
Number of subjects: 25
Study 20843608 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 25
Study 18816008 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-focused therapy
Number of subjects: 34
Study 18816008 — intervention group
Group type: COMPARATOR
Intervention: Client-centered therapy
Number of subjects: 34
Study 17165303 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect resin composite
Number of subjects: 32
Study 17165303 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct resin composite
Number of subjects: 32
Study 17165303 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tooth wear)
Number of subjects: 32
Study 15458066 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Neurofeedback Training (VRNT)
Number of subjects: 50
Study 15458066 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Cognitive Training (VRCT)
Number of subjects: 50
Study 15458066 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no training)
Number of subjects: 50
Study 15458066 — intervention group
Group type: COMPARATOR
Intervention: Placebo Groups (desktop training)
Number of subjects: 50
Study 10901907 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated (twice daily) radiotherapy
Number of subjects: 76
Study 10901907 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 76
Study 8746831 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeded grafts
Number of subjects: 32
Study 8746831 — intervention group
Group type: COMPARATOR
Intervention: Control grafts
Number of subjects: 32
Study 2184355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (4 mg per kilogram of body weight per day)
Number of subjects: 29
Study 2184355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 6112932 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 116
Study 6112932 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovar
Number of subjects: 116
Study 6112932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 30621702 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPG SNPs (rs3813082, rs2000813, rs2097055, rs3819166)
Number of subjects: 2498
Study 30621702 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPG SNP rs2000813
Number of subjects: 2498
Study 30621702 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPG SNP rs2097055 and ApoA1 (rs3819166)
Number of subjects: 2498
Study 30621702 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotypes (rs3813082T-rs2000813C-rs2097055T-rs3819166A)
Number of subjects: 2498
Study 30621702 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotypes
Number of subjects: 2498
Study 28238332 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate
Number of subjects: 125
Study 28238332 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis
Number of subjects: 125
Study 28238332 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb extract
Number of subjects: 125
Study 28238332 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut extract
Number of subjects: 125
Study 28238332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 25787997 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potassium, high-sodium meal (HKHN)
Number of subjects: 39
Study 25787997 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-potassium, high-sodium meal (LKHN)
Number of subjects: 39
Study 25787997 — intervention group
Group type: COMPARATOR
Intervention: Control meal (low-potassium, low-sodium meal)
Number of subjects: 39
Study 23866823 — intervention group
Group type: COMPARATOR
Intervention: 1 mg/kg benralizumab (single-dose intravenous)
Number of subjects: 27
Study 23866823 — intervention group
Group type: COMPARATOR
Intervention: 100 or 200 mg benralizumab (3 monthly subcutaneous doses)
Number of subjects: 27
Study 20883988 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop ligation combined with vasopressin
Number of subjects: 105
Study 20883988 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin alone
Number of subjects: 105
Study 20883988 — intervention group
Group type: COMPARATOR
Intervention: Neither loop ligation nor vasopressin
Number of subjects: 105
Study 19587470 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen sustained release (SR)
Number of subjects: 90
Study 19587470 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen gastro-retentive system (GRS)
Number of subjects: 90
Study 19587470 — intervention group
Group type: COMPARATOR
Intervention: Baclofen immediate release (IR)
Number of subjects: 90
Study 18001201 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (32‐33 degrees C) maintained for 48 h
Number of subjects: 36
Study 18001201 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (control group)
Number of subjects: 36
Study 15304046 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (9000 IU of four heparins of different mol. wt distributions)
Number of subjects: 12
Study 15304046 — intervention group
Group type: COMPARATOR
Intervention: Activated Partial Thromboplastin Time (APTT)
Number of subjects: 12
Study 15304046 — intervention group
Group type: COMPARATOR
Intervention: Endogenous Thrombin Potential (ETP)
Number of subjects: 12
Study 11402638 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 8 mg + Oral Contraceptive (OC)
Number of subjects: 34
Study 11402638 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (P) + Oral Contraceptive (OC)
Number of subjects: 34
Study 9415909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet pressures set 50 mm above occlusion pressures
Number of subjects: 29
Study 9415909 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum mean pressures in upper extremity group
Number of subjects: 29
Study 9415909 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum mean pressures in lower extremity group
Number of subjects: 29
Study 7904085 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with disease-modifying antirheumatic drugs (DMARDs), specific details on dosage and duration not available.
Number of subjects: 0
Study 7904085 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 3480374 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (deriving 20% of energy from fat)
Number of subjects: 33
Study 3480374 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (deriving 40% of energy from fat)
Number of subjects: 33
Study 31126915 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 0
Study 27641686 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive screen for anxiety
Number of subjects: 2156
Study 27641686 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive screen for depression
Number of subjects: 2156
Study 27641686 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling anxious item
Number of subjects: 2156
Study 27641686 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry item
Number of subjects: 2156
Study 25772594 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcitriol therapy
Number of subjects: 35
Study 25772594 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 35
Study 23831920 — intervention group
Group type: EXPERIMENTAL
Intervention: TET2 mutated cases
Number of subjects: 100
Study 23831920 — intervention group
Group type: COMPARATOR
Intervention: TET2 wild-type cases
Number of subjects: 100
Study 21734418 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus docetaxel (XT)
Number of subjects: 68
Study 21734418 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin plus docetaxel (ET)
Number of subjects: 68
Study 19857636 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Serving
Number of subjects: 19
Study 19857636 — intervention group
Group type: COMPARATOR
Intervention: Standard
Number of subjects: 19
Study 16920898 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/atorvastatin calcium combination tablet (10/80 mg; n = 62)
Number of subjects: 126
Study 16920898 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/atorvastatin calcium combination tablet (5/10 mg; n = 64)
Number of subjects: 126
Study 15494466 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 94
Study 15494466 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT; conjugated estrogens, 0.625 mg/d; trimonthly medroxyprogesterone acetate, 5 mg/d for 13 d)
Number of subjects: 94
Study 15494466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 10932308 — intervention group
Group type: EXPERIMENTAL
Intervention: Purposeful activity (play activity)
Number of subjects: 2
Study 10932308 — intervention group
Group type: COMPARATOR
Intervention: Rote exercise
Number of subjects: 2
Study 9155120 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelseal (g-G0, n = 7)
Number of subjects: 15
Study 9155120 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemashield (g-H0, n = 8)
Number of subjects: 15
Study 9155120 — intervention group
Group type: COMPARATOR
Intervention: Hemashield (g-H, n = 7)
Number of subjects: 15
Study 9155120 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelseal (g-G, n = 5)
Number of subjects: 15
Study 9155120 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (g-G and g-H)
Number of subjects: 15
Study 9155120 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelseal (g-G)
Number of subjects: 15
Study 9155120 — intervention group
Group type: COMPARATOR
Intervention: Hemashield (g-H)
Number of subjects: 15
Study 8399497 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% podophyllotoxin lotion
Number of subjects: 205
Study 8399497 — intervention group
Group type: COMPARATOR
Intervention: 25% podophyllin solution
Number of subjects: 205
Study 3527643 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse-chestnut seed extract (Venostasin retard) 600 mg (two capsules of 50 mg aescin each)
Number of subjects: 22
Study 3527643 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical-looking capsule)
Number of subjects: 22
Study 3414574 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 99
Study 3414574 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 99
Study 3414574 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A plus Iron supplementation
Number of subjects: 99
Study 3414574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 30872203 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-channel group
Number of subjects: 150
Study 30872203 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard-channel group
Number of subjects: 150